BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
CEO
Neil Kumar
Headquarters
3160 PORTER DR., SUITE 250
PALO ALTO, CA 94304, UNITED STATES
Share Price x Number of Outstanding Shares The total market value of a company's outstanding shares. Used to categorize companies by size (small, mid, large-cap).
Covariance of stock return with market return / Variance of market return Measure of stock's volatility in relation to the overall market. 1 suggests similar volatility to the market.
Net Income / Average Outstanding Shares The portion of a company's profit allocated to each outstanding share. Higher values are generally better, sector-dependent.
Share Price / Book Value Per Share Compares a company's market value to its book value. Under 1 could mean undervalued, over 3 might be overvalued.
Operating Income / Net Sales Proportion of a company's revenue left after paying for production variable costs. 15% or higher is often good.
Total Liabilities / Shareholder's Equity Proportion of equity and debt used to finance a company's assets. Above 2.0 might indicate high risk.
Share Price / EPS Measures share price relative to earnings per share. Lower than industry average may indicate undervaluation.
Net Income / Shareholder's Equity Profitability of a corporation in relation to stockholders' equity. 15% or more is generally considered good.
Current Assets / Current Liabilities Company’s ability to pay short-term obligations. Above 1 indicates good financial health.
Operating Cash Flow - Capital Expenditures Actual cash generated by a company's operations for expansion, dividends, and debt reduction. Positive FCF preferred, the larger the better.